Results 61 to 70 of about 38,769 (305)

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Effect of sodium-glucose Co-transporter 2 inhibitors on coronary microcirculation

Frontiers in Pharmacology
Coronary microvascular disease (CMVD) has emerged as a new target for the occurrence and development of heart failure treatment. Various indicators such as Index of Microvascular Resistance, Coronary Flow Reserve, Microvascular Resistance Reserve ...
Shaoxin Chen, Weiqian Ou, Shuguang Gan, Lixian Chen, Baohua Liu, Zhenhong Zhang   +5 more
doaj   +1 more source

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors [PDF]

, 2022
Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic regulation in diabetes.
Salvatore T., Rinaldi L., Sardu C., Docimo G., Albanese G., Di Salvo J., Lettieri M., Marfella R., Di Martino A., Caturano A., Sasso F. C., Galiero R., Epifani R.   +12 more
core   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source

Practical Considerations and Implementation of Sodium-Glucose Co-Transporter-2 Inhibitors in Chronic Kidney Disease: Who, When, and How? A Position Statement by Nephrologists

Journal of Primary Care & Community Health
Introduction: There remains an unmet need to reduce kidney and cardiovascular risk in patients with chronic kidney disease (CKD). This report is therefore intended to provide real-world clinical guidance to primary care providers on sodium-glucose co ...
Anjay Rastogi, Ashté Collins, Ellie Kelepouris, Wayne Kotzker, John P. Middleton, Minesh Rajpal, Prabir Roy-Chaudhury, Glenn M. Chertow   +7 more
doaj   +1 more source

Efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with acute heart failure: a systematic review and meta-analysis

Frontiers in Cardiovascular Medicine
BackgroundThe effectiveness and safety of a novel class of hypoglycemic medications known as sodium-glucose cotransporter 2 (SGLT2) inhibitors have not been completely established in relation to acute heart failure (AHF).
Jingjin Hou, Li Ren, Qingbin Hou, Xiaodong Jia, Zhu Mei, Jiaxin Xu, Zheming Yang, Yiming Li, Chenghui Yan   +8 more
doaj   +1 more source

The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management

Cardiovascular Diabetology, 2022
Type 2 diabetes mellitus (T2DM) is a chronic, complex metabolic disease characterized by chronic hyperglycemia causing from insufficient insulin signaling because of insulin resistance or defective insulin secretion, and may induce severe complications ...
Bo Xu, Shaoqian Li, Bo Kang, Jiecan Zhou
doaj   +1 more source

Is cancer incidence modified by SGLT2 inhibitors? [PDF]

, 2019
One of the most important achievements of diabetology in the second decade of the 21st century is undoubtedly the introduction of sodium-glucose cotransporter (SGLT2) inhibitors into clinical practice as a new class of glucose-lowering agents for type 2 ...
Lev M. Berstein
core   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source

The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) [PDF]

Hospital Pharmacology
Introduction: Sodium-glucose cotransporter type 2 (SGLT2) inhibitors play a crucial role in type 2 diabetes treatment, exerting effects on proximal tubules to reduce glucose reab-sorption and enhance urinary excretion, offering cardiovascular and ...
Denda Nikola I., Maletin Nemanja Z., Atanasković Marko B., Vučković Biljana A., Rašković Aleksandar L.   +4 more
doaj   +1 more source